Literature DB >> 19809056

Low-dose urokinase in massive pulmonary embolism when standard thrombolysis is contraindicated.

Pierre Bulpa1, Guiseppe Carbutti2, Jean-Claude Osselaer3, Georges Lawson4, Alain Dive5, Patrick Evrard5.   

Abstract

When acute massive pulmonary embolism is life threatening, thrombolysis could be a therapeutic option. However, lysis may be contraindicated once the risk of bleeding is high. We report on two patients who have massive pulmonary emboli complicated by severe hypotension, justifying thrombolytic treatment. Nevertheless, recent surgery in the first patient and a fresh hemorrhagic duodenal ulcer in the second patient precluded thrombolytic treatment at the usual dosage. Therefore, prolonged lysis with low-dose urokinase (1,000 units/kg/h) was initiated. After a few hours, the patients became hemodynamically stable and inotrope/vasopressor doses could be reduced and stopped. No major bleeding was observed. Consequently, prolonged thrombolysis with low-dose urokinase could be an alternative approach to therapy in patients with massive pulmonary emboli when recommended thrombolytic dosages are contraindicated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19809056     DOI: 10.1378/chest.08-2583

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  1 in total

1.  Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study.

Authors:  Cuilian Weng; Xincai Wang; Long Huang; Xingsheng Lin; Qinghua Liu
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.